Clinical practice and implications of biomarker testing in biliary tract cancer
Recent Publication
A large observational study with 1,521 patients from 18 centres in Germany and Austria reveals that biomarker tests for bile duct cancer vary greatly in practice. Different sequencing methods lead to variable results, although 40 per cent of cases have treatable genetic changes such as HER2, BRAF or FGFR2. Only 13 per cent of those affected received suitable targeted therapies and lived significantly longer as a result - 31.8 instead of 22.8 months. OA PD Dr Hossein Taghizadeh MSc PhD from St. Pölten University Hospital was a co-author of this study.
Welland, S., Zöller, A. K., Mavroeidi, I. A., Tomczak, A., Müller, C., Yawen, D., Zhang, D., Keil, F., Pangerl, M., Zhou, T., Taghizadeh, H., Lange, S., Kinzler, M. N., Shmanko, K., Barsch, M., Zimpel, C., Djanani, A., Schulze-Bergkamen, H., Keyl, J., ... Vogel, A. (2026). Clinical practice and implications of biomarker testing in biliary tract cancer: An observational study. JHEP Reports, 8(1), Article 101635. https://doi.org/10.1016/j.jhepr.2025.101635
OA PD Dr. Hossein Taghizadeh MSc PhD
Division of Internal Medicine 1 (University Hospital St. Pölten)